HowShorted

How shorted is ImmunityBio, Inc.?

More shorted than 87% of the 2,877 ranked US companies

12.17%
of shares outstanding reported short · settlement date 31 Jul 2026
vs previous report
−0.66
5 reports (~10 weeks)
−0.51
Aggregate net short position time series for ImmunityBio, Inc.
Embed this chart

Paste this snippet to embed the interactive chart. It updates with each FINRA report and keeps the source attribution. Preview

Cite this page

History

Settlement dateShort %Change
31 Jul 202612.17%−0.66
15 Jul 202612.83%+0.24
30 Jun 202612.59%−0.31
15 Jun 202612.90%+0.28
29 May 202612.62%−0.06
15 May 202612.68%−1.34
30 Apr 202614.02%−0.23
15 Apr 202614.25%+0.49
31 Mar 202613.76%+0.14
13 Mar 202613.62%+0.17
27 Feb 202613.45%−0.23
13 Feb 202613.68%−0.04
30 Jan 202613.72%+0.83
15 Jan 202612.89%+0.64
31 Dec 202512.25%+1.18
15 Dec 202511.07%+2.08
28 Nov 20258.99%+0.76
14 Nov 20258.23%+0.74
31 Oct 20257.49%−0.19
15 Oct 20257.68%−0.09
30 Sep 20257.77%−1.18
15 Sep 20258.95%+0.98
29 Aug 20257.97%+0.02
15 Aug 20257.95%−0.20
31 Jul 20258.15%–

Frequently asked questions

How shorted is ImmunityBio, Inc. right now?
12.17% of ImmunityBio, Inc.'s (IBRX) shares outstanding were reported short for settlement date 31 Jul 2026, per FINRA's consolidated short interest report.
What does this number include?
FINRA member firms must report their short positions in all US equities twice a month; FINRA consolidates them per security. We divide that official share count by the company's shares outstanding from its SEC filings. This is the regulatory figure, not a daily estimate.
Why does it only update twice a month?
US short interest is reported for settlement on the 15th and the last business day of each month, and FINRA publishes the consolidated figures about nine business days later. That cadence is set by regulation; no daily official figure exists.
Which funds are short?
US public short interest is aggregate-only: individual short sellers are not named. Only some EU markets publish named positions.